Abstract:Meconium aspiration syndrome (MAS) is an important cause of respiratory distress in the term infant. Therapy for the disease remains problematic, and newer treatments such as high-frequency ventilation and inhaled nitric oxide are being applied with increasing frequency. There is a significant disturbance of the pulmonary surfactant system in MAS, with a wealth of experimental data indicating that inhibition of surfactant function in the alveolar space is an important element of the pathophysiology of the disease. This inhibition may be mediated by meconium, plasma proteins, haemoglobin and oedema fluid, and, at least in vitro, can be overcome by increasing surfactant phospholipid concentration. These observations have served as the rationale for administration of exogenous surfactant preparations in MAS, initially as standard bolus therapy and, more recently, in association with therapeutic lung lavage. Bolus surfactant therapy in ventilated infants with MAS has been found to improve oxygenation in most studies, although there are a significant proportion of nonresponders and in many cases the effect is transient. Pooled data from randomised controlled trials of surfactant therapy suggest a benefit in terms of a reduction in the requirement for extracorporeal membrane oxygenation (relative risk 0.48 in surfactant-treated infants) but no diminution of air leak or ventilator days. Current evidence would support the use of bolus surfactant therapy on a case by case basis in nurseries with a relatively high mortality associated with MAS, or the lack of availability of other forms of respiratory support such as high-frequency ventilation or nitric oxide. If used, bolus surfactant should be administered as early as practicable to infants who exhibit significant parenchymal disease, at a phospholipid dose of at least 100 mg/kg, rapidly instilled into the trachea. Natural surfactant or a third-generation synthetic surfactant should be used and the dosage repeated every 6 hours until oxygenation has improved. Lung lavage with dilute surfactant has recently emerged as an alternative to bolus therapy in MAS, which has the advantage of removing surfactant inhibitors from the alveolar space in addition to augmenting surfactant phospholipid concentration. Combined animal and human data suggest that lung lavage can remove significant amounts of meconium and alveolar debris, and thereby improve oxygenation and pulmonary mechanics. Arterial oxygen saturation inevitably falls during lavage but has been noted to recover relatively rapidly, even in infants with severe disease. Several randomised controlled trials of surfactant lavage in MAS are underway, and until the results are known, lavage must be considered an unproven and experimental therapy.

Meconium aspiration syndrome requiring assisted ventilation: perspective in a setting with limited resources

Meconium aspiration syndrome: a comprehensive review

Advances in the Management of Meconium Aspiration Syndrome

Risk factors of mortality in meconium aspiration syndrome: review of 314 cases.

Treatment of Severe Meconium Aspiration Syndrome with Porcine Surfactant: A Multicentre, Randomized, Controlled Trial

[Clinical features and prognosis of meconium aspiration syndrome complicated by pulmonary hemorrhage in neonates]

Neonatal Respiratory Distress Secondary to Meconium Aspiration Syndrome

Risk factors of Neonatal death in Meconium Aspiration Syndrome

Extracorporeal Membrane Oxygenation as Treatment of Severe Meconium Aspiration Syndrome

Risk factors and complications of severe meconium aspiration syndrome in neonates

The prevalence of pulmonary artery hypertension in neonates with meconium aspiration syndrome: a prospective study

Clinical features and prognosis of severe meconium aspiration syndrome with acute respiratory distress syndrome

Risk factors of meconium aspiration syndrome developing into persistent pulmonary hypertension of newborn.

Clinical characteristics of meconium aspiration syndrome in neonates with different gestational ages and the risk factors for neurological injury and death: A 9-year cohort study

Risk factors and outcomes for ventilator-associated pneumonia in neonatal intensive care unit patients.

Meconium aspiration syndrome and neonatal outcome in a developing country

A population-based evaluation of sustained mechanical ventilation of newborn babies

Perioperative Risk Factors for Prolonged Mechanical Ventilation Following Cardiac Surgery in Neonates and Young Infants.

MORBIDITY AND MORTALITY PROFILE OF BABIES BORN THROUGH MECONIUM STAINED AMNIOTIC FLUID AND ADMITTED IN NEONATAL INTENSIVE CARE UNIT (NICU) OF TERTIARY CARE HOSPITAL IN NORTH INDIA

Surfactant therapy for meconium aspiration syndrome: current status

Effect of Nasal Continuous Positive Airway Pressure on Infants With Meconium Aspiration Syndrome: A Randomized Clinical Trial